PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
1 other identifier
observational
1,690
1 country
45
Brief Summary
The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2011
Longer than P75 for all trials
45 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 9, 2011
CompletedFirst Posted
Study publicly available on registry
August 11, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2018
CompletedJune 13, 2019
June 1, 2019
6.7 years
August 9, 2011
June 11, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
A source of observational data that can be used to report and query patient care patterns, clinical outcomes and trends from high dose IL-2 or Proleukin therapy in treating malignant melanoma, or renal cell carcinoma or other malignancies.
12 months
Eligibility Criteria
All patients starting high dose IL-2 or Proleukin therapy are eligible to participate
You may qualify if:
- years or older
- Must have received at least one course of high dose IL-2 or Proleukin
- Signed informed consent form
You may not qualify if:
- Prior high dose IL-2 or Proleukin therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (45)
The University of Arizona Cancer Center
Tucson, Arizona, 85742, United States
Moores UCSD Cancer Center
La Jolla, California, 92093, United States
USC Norris Cancer Center
Los Angeles, California, 90089, United States
Southern California Permanente Medical Group
Riverside, California, 92505, United States
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
University of Miami
Miami, Florida, 33136, United States
Mount Sinai Medical Center Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
University of Hawaii
Honolulu, Hawaii, 96822, United States
Rush Pres St Lukes Medical Center
Chicago, Illinois, 60612, United States
Loyola University Medical Center
Maywood, Illinois, 60153, United States
Oncology Specialists, SC
Park Ridge, Illinois, 60068, United States
Indiana University Melvin and Bren Simon Center
Indianapolis, Indiana, 46202, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
University of Kansas Hospital
Kansas City, Kansas, 66160, United States
The Baton Rouge Clinic, AMC
Baton Rouge, Louisiana, 70808, United States
Johns Hopkins
Lutherville, Maryland, 21093, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Saint Louis University Cancer Center
St Louis, Missouri, 63110, United States
Midwest Cancer Center - Legacy
Omaha, Nebraska, 68130, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
Saint Luke's-Roosevelt Hospital Center
New York, New York, 10019, United States
Columbia University/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
The Research Foundation for The State University of New York
Syracuse, New York, 13210, United States
Blumenthal Cancer Center
Charlotte, North Carolina, 28203, United States
Duke University Medical Center
Durham, North Carolina, 27705, United States
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States
The Christ Hospital Cancer Center
Cincinnati, Ohio, 45219, United States
University of Cincinnati Cancer Institute
Cincinnati, Ohio, 45267, United States
University Hospitals Siedman Cancer Center
Cleveland, Ohio, 44106, United States
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Saint Luke's Hospital and Health Network
Bethlehem, Pennsylvania, 18015, United States
The Pennsylvania State University and The Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
Hillman Cancer Research Pavilion, Div. of Medical Oncology
Pittsburgh, Pennsylvania, 15232, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84132, United States
University of Washington
Seattle, Washington, 98195, United States
Wheaton Franciscan Cancer Care
Franklin, Wisconsin, 53132, United States
Related Publications (2)
Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. J Immunother Cancer. 2019 Mar 27;7(1):84. doi: 10.1186/s40425-019-0567-3.
PMID: 30917871DERIVEDCurti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017 Dec 19;5(1):102. doi: 10.1186/s40425-017-0307-5.
PMID: 29254506DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Michael Wong, MD
MD Anderson
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 9, 2011
First Posted
August 11, 2011
Study Start
August 1, 2011
Primary Completion
April 1, 2018
Study Completion
May 1, 2018
Last Updated
June 13, 2019
Record last verified: 2019-06